The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is low avidity with antitumor activity

European Journal of Immunology

Volumn 34, Issue 3, 2004, Pages 752-761

  Lustgarten, Joseph ^a   Dominguez, Ana Lucia ^a   Cuadros, Camilo ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

Antigens; CTL; Peptides; Tolerance; Tumor immunology; Vaccination

Indexed keywords

CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GENE PRODUCT; MONOCLONAL ANTIBODY; PEPTIDE; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; CD134 ANTIGEN; HLA A2 ANTIGEN; TNFRSF4 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DATA ANALYSIS; GENE OVEREXPRESSION; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION; WILD TYPE; ADOPTIVE TRANSFER; ANIMAL; CELL DIVISION; COMPARATIVE STUDY; DENDRITIC CELL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL DIVISION; CELL LINE, TUMOR; DENDRITIC CELLS; HLA-A2 ANTIGEN; IMMUNE TOLERANCE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PEPTIDES; RECEPTOR, ERBB-2; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, CYTOTOXIC;

EID: 1642316449     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200324427     Document Type: Article

References (31)

1. - transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989. 58: 293-303.
2. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A. and Boon, T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991. 254: 1643-1647.
3. Valmori, D., Levy, F., Miconnet, I., Zajac, P., Spagnoli, G. C., Rimoldi, D., Lienard, D., Cerundolo, V., Cerottini, J. C. and Romero, P., Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 2000. 164: 1125-1131.
4. Rosenberg, S. A., A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999. 10: 281-287.
5. Levitsky, H. I., Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T cell tolerance. Cancer J. 2000. 6 Suppl. 3: S281-290.
6. Ferber, I., Schonrich, G., Schenkel, J., Mellor, A. L., Hammerling, G. J. and Arnold, B., Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 1994. 263: 674-676.
7. Kawai, K. and Ohashi, P. S., Immunological function of a defined T cell population tolerized to low-affinity self antigens. Nature 1995. 374: 68-69.
8. Hausmann, S., Martin, M., Gauthier, L. and Wucherpfennig, K. W., Structural features of autoreactive TCR that determine the degree of degeneracy in peptide recognition. J. Immunol. 1999. 162: 338-344.
9. Morgan, D. J., Kreuwel, H. T., Fleck, S., Levitsky, H. I., Pardoll, D. M. and Sherman, L. A., Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 1998. 160: 643-651.
10. Mullins, D. W., Bullock, T. N., Colella, T. A., Robila, V. V. and Engelhard, V. H., Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA A*0201-transgenic mice. J. Immunol. 2001. 167: 4853-4860.
11. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R. and Leder, P., Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988. 54: 105-115.
12. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D. and Muller, W. J., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992. 89: 10578-10582.
13. Shimizu, K., Fields, R. C., Giedlin, M. and Mule, J. J., Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 1999. 96: 2268-2273.
14. + memory T cells. J. Immunol. 2000. 165: 3031-3036.
15. Gramaglia, I., Weinberg, A. D., Lemon, M. and Croft, M., Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 1998. 161: 6510-6517.
16. Rogers, P. R., Song, J., Gramaglia, I., Killeen, N. and Croft, M., OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001. 15: 445-455.
17. Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C. and Shields, J., Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000. 164: 2160-2169.
18. Pan, P. Y., Zang, Y., Weber, K., Meseck, M. L. and Chen, S. H., OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 2002. 6: 528-536.
19. Lustgarten, J., Theobald, M., Labadie, C., LaFace, D., Peterson, P., Disis, M. L., Cheever, M. A. and Sherman, L. A., Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum. Immunol. 1997. 52: 109-118.
20. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A. and Chesnut, R. W., Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 1991. 173: 1007-1015.
21. Reilly, R. T., Gottlieb, M. B., Ercolini, A. M., Machiels, J. P., Kane, C. E., Okoye, F. I., Muller, W. J., Dixon, K. H. and Jaffee, E. M., HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 2000. 60: 3569-3576.
22. Kurt, R. A., Whitaker, R., Baher, A., Seung, S. and Urba, W. J., Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice. Int. J. Cancer 2000. 87: 688-694.
23. Reilly, R. T., Machiels, J. P., Emens, L. A., Ercolini, A. M., Okoye, F. I., Lei, R. Y., Weintraub, D. and Jaffee, E. M., The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 2001. 61: 880-883.
24. Lollini, P. L., Nicoletti, G., Landuzzi, L., De Giovanni, C., Rossi, I., Di Carlo, E., Musiani, P., Muller, W. J. and Nanni, P., Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer 1998. 77: 937-941.
25. Theobald, M., Biggs, J., Hernandez, J., Lustgarten, J., Labadie, C. and Sherman, L. A., Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 1997. 185: 833-841.
26. Chen, Y., Hu, D., Eling, D. J., Robbins, J. and Kipps, T. J., DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res. 1998. 58: 1965-1971.
27. Cordaro, T. A., de Visser, K. E., Tirion, F. H., Schumacher, T. N. and Kruisbeek, A. M., Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J. Immunol. 2002. 168: 651-660.
28. Ercolini, A. M., Machiels, J. P., Chen, Y. C., Slansky, J. E., Giedlen, M., Reilly, R. T. and Jaffee, E. M., Identification and characterization of the immunodominant rat HER-2/neu MHC cClass I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J. Immunol. 2003. 170: 4273-4280.
29. de Visser, K. E., Cordaro, T. A., Kioussis, D., Haanen, J. B., Schumacher, T. N. and Kruisbeek, A. M., Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur. J. Immunol. 2000. 30: 1458-1468.
30. De Smedt, T., Smith, J., Baum, P., Fanslow, W., Butz, E. and Maliszewski, C., Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 2002. 168: 661-670.
31. Cuadros, C. D. A., Frost, G., Borgstrom P. and Lustgarten, J., Cooperative effect between immunotherapy and antiangiogenic therapy results in effective tumor rejection in tolerant Her-2/neu mice. Cancer Res. 2003. 63: 5895-5901.